Chemistry:Vorolanib
From HandWiki
Vorolanib is a drug with antiangiogenic and antineoplastic activities.[1] In 2023, vorolanib was approved for use in China. It is used in combination with everolimus for the treatment of advanced renal cell carcinoma in patients who have previously received tyrosine kinase inhibitor treatment but failed.[2]
Vorolanib is also being evaluated for the treatment of neovascular age‑related macular degeneration.[3]
It is a dual inhibitor that targets both vascular endothelial growth factor receptors (VEGFRs) and platelet-derived growth factor receptors (PDGFRs).[4]
References
- ↑ "Vorolanib, a novel tyrosine receptor kinase receptor inhibitor with potent preclinical anti-angiogenic and anti-tumor activity". Molecular Therapy Oncolytics 24: 577–584. March 2022. doi:10.1016/j.omto.2022.01.001. PMID 35252556.
- ↑ "Vorolanib Tablets Approved for Marketing by China NMPA". National Medical Products Administration. 2023-06-08. https://english.nmpa.gov.cn/2023-06/08/c_940308.htm.
- ↑ "Role of alternative oral therapy for the management of wet age-related macular degeneration and proliferative diabetic retinopathy". World Journal of Diabetes 16 (8). August 2025. doi:10.4239/wjd.v16.i8.109231. PMID 40837344.
- ↑ "Vorolanib". NCI Drug Dictionary. National Cancer Institute. https://www.cancer.gov/publications/dictionaries/cancer-drug/def/vorolanib.
 |  |
